Published IFRS-based supplementary materials for FY2026 Q2. Revenue was 266.5 hundred million yen, up 17.3% year-over-year; core operating profit declined sharply to 42.1 hundred million yen; overseas sales ratio expanded to 83.2%. Earnings forecasts were revised.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4506-20261030-02.pdf","jir_short_summary":"Published IFRS-based supplementary materials for FY2026 Q2. Revenue was 266.5 hundred million yen, up 17.3% year-over-year; core operating profit declined sharply to 42.1 hundred million yen; overseas sales ratio expanded to 83.2%. Earnings forecasts were revised.","jir_summary":"### Performance Overview\nThe supplementary materials for Sumitomo Pharma Co., Ltd.'s FY2026 Q2 disclose consolidated results on an IFRS basis. While revenue increased significantly year-over-year, both core operating profit and operating profit declined substantially. The rise in overseas ratio (83.2%) is notable, and foreign exchange effects and changes in cost structure have impacted profitability.\n\n### Impact and Outlook\nAlthough revenue is expanding, increased costs and higher research and development spending have depressed profits, particularly resulting in a large decline in core operating profit. Earnings forecasts have been revised, and future currency movements and the progress of new drug development will be key factors.","jir_financial_highlights":"Revenue (core basis): 2,665 (FY2025 Q2 actual 2,271\u2192FY2026 Q2 actual 2,665 Change 394 Change rate +17.3%)\nCost of sales: 1,235 (FY2025 Q2 actual 897\u2192FY2026 Q2 actual 1,235 Change 338 Change rate +37.7%)\nGross profit: 1,430 (FY2025 Q2 actual 1,374\u2192FY2026 Q2 actual 1,430 Change 55 Change rate +4.0%)\nSelling, general and administrative expenses: 783 (FY2025 Q2 actual 766\u2192FY2026 Q2 actual 783 Change 44 Change rate +5.9%)\nResearch and development expenses: 238 (FY2025 Q2 actual 175\u2192FY2026 Q2 actual 238 Change 63 Change rate +35.9%)\nCore operating profit: 421 (FY2025 Q2 actual 961\u2192FY2026 Q2 actual 421 Decrease -540 Change rate -56.2%)\nOperating profit: 423 (FY2025 Q2 actual 962\u2192FY2026 Q2 actual 423 Decrease -539 Change rate -56.0%)\nProfit attributable to owners of parent (interim): 382 (FY2025 Q2 actual 989\u2192FY2026 Q2 actual 382 Decrease -606 Change rate -61.3%)","jir_category":"","jir_hashtags":"#SumitomoPharma, #SupplementaryResults, #IFRS, #PharmaceuticalDevelopment","jir_key_figures":"FY2026 Q2 Revenue: 2,665 hundred million yen\nCore operating profit: 421 hundred million yen\nProfit attributable to owners of parent (interim): 382 hundred million yen","jir_meta_title":"Sumitomo Pharma Co., Ltd. \u2013 FY2026 Q2 Supplementary Materials | Revenue Growth and Profit Headwinds","jir_meta_description":"Summary of Sumitomo Pharma Co., Ltd.'s FY2026 Q2 supplementary materials. Revenue up +17.3% YoY to 266.5 hundred million yen, core operating profit decreased substantially; expansion of overseas ratio and higher R&D spending are key points. Outlines outlook and factors behind revisions.","jir_og_title":"Sumitomo Pharma Co., Ltd. \u2013 Q2 Supplementary Materials | Revenue Growth and Profit Headwinds","jir_og_description":"Summary of Sumitomo Pharma Co., Ltd.'s FY2026 Q2 supplementary materials: revenue expanded but profits declined. Explains outlook and factors behind revisions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138889","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n